Azitra vs Genelux
AZTR and GNLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AZTR and GNLX compare
Genelux is the larger company, worth 23 times as much as Azitra ($84.4M against $3.7M).
Genelux scores higher on the StockData Score (5 against 2 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AZTR | GNLX |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $84.4M |
| Share price | $0.608 | $1.86 |
| Change, 1 year | 50.2% | −68.5% |
| Beta (5Y) | −2.26 | 0.61 |
| Employees | 13 | – |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× (better) | 5.2× |
| FCF yield | −316% | −34.0% (better) |
| Profitability | ||
| Return on equity | −373% | −178% (better) |
| Return on invested capital | −1294% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1220.4× | – |
| Current ratio | 3.11 (better) | 2.39 |
| Altman Z-score | −23.30 | −15.19 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | −70.9% | −22.4% (better) |
| Shareholder yield | −70.9% | −22.4% (better) |
| Ownership | ||
| Held by institutions | – | 21.7% |
| Held by insiders | 95.8% | 7.7% |
| Insider net buying, 12 months | – | −$341K |
| Short interest, % of float | 121% | 10.9% |
Go deeper
- AZTR stock overview
- AZTR income statement
- AZTR valuation and score
- GNLX stock overview
- GNLX income statement
- GNLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.